as 10-14-2025 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Founded: | 2014 | Country: | United Kingdom |
Employees: | N/A | City: | LONDON |
Market Cap: | 8.6B | IPO Year: | N/A |
Target Price: | $19.94 | AVG Volume (30 days): | 8.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.69 | EPS Growth: | N/A |
52 Week Low/High: | $8.73 - $16.79 | Next Earning Date: | 11-11-2025 |
Revenue: | $23,233,000 | Revenue Growth: | -35.86% |
Revenue Growth (this year): | -20.23% | Revenue Growth (next year): | 200.91% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Venker Eric | ROIV | President & Immunovant CEO | Oct 8 '25 | Sell | $16.20 | 138,602 | $2,245,352.40 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Oct 7 '25 | Sell | $16.15 | 355,161 | $5,735,850.15 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Oct 6 '25 | Sell | $16.34 | 171,396 | $2,800,610.64 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Sep 23 '25 | Sell | $14.83 | 611,000 | $9,061,130.00 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Sep 22 '25 | Sell | $15.00 | 416,182 | $6,240,568.18 | 1,504,959 | |
Venker Eric | ROIV | President & Immunovant CEO | Sep 19 '25 | Sell | $14.95 | 683,818 | $10,223,079.10 | 1,504,959 | |
Gline Matthew | ROIV | CEO | Sep 18 '25 | Buy | $15.07 | 3,315 | $49,957.05 | 17,287,081 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 5 '25 | Sell | $12.96 | 385,816 | $5,000,175.36 | 35,508,359 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 4 '25 | Sell | $12.92 | 194,933 | $2,518,534.36 | 35,508,359 | |
Ramaswamy Vivek | ROIV | 10% Owner | Sep 3 '25 | Sell | $12.50 | 1,195,000 | $14,937,500.00 | 35,508,359 |
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
Simply Wall St.
11 days ago
Benzinga
15 days ago
Reuters
23 days ago
Insider Monkey
a month ago
Zacks
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.